



Candidas[®] (caspofungin acetate) – First-time generic

- On August 1, 2017, Fresenius announced the launch of an **AP-rated** generic equivalent of Merck's **Candidas (caspofungin acetate)** injection, indicated in adults and pediatric patients (3 months of age and older) for:
 - Empirical therapy for presumed fungal infections in febrile, neutropenic patients.
 - Treatment of candidemia and the following Candida infections: intra-abdominal abscesses, peritonitis and pleural space infections.
 - Treatment of esophageal candidiasis.
 - Treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies.
- The **2016 global market sales** for Candidas were \$558 million.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.